Treatment-Naïve GPRC5D-Negative Multiple Myeloma With t(11;14) (IMS 2026) - Sep 11, 2026 - Abstract #PA-504; Pres time: Sep 23, 2026; P1 | "Clinical validation was performed in 32 RRMM patients enrolled in two anti-GPRC5D CART trials (NCT04555551, NCT05431608) and 117 patients treated with Talquetamab...As additional validation, in the Talquetamab cohort (n=117), patients with t(11;14) and prior Venetoclax sensitivity showed no GPRC5D expression and primary refractoriness to anti-GPRC5D... This study identifies a strong association of GPRC5D negativity with a t(11;14), B-cell-like profile, and genomically indolent myeloma subgroup, potentially conferring refractoriness to anti-GPRC5D therapy. As this group accounts for 10% of NDMM, and GPRC5D protein measurement can be performed by IHC, this represents a feasible and accessible biomarker for immunotherapy selection in myeloma. Importantly, these patients usually have a genomically indolent profile and are particularly sensitive to anti-BCMA therapies (Maura et al."
IO biomarker • Hematological Malignancies • Multiple Myeloma • CD2 • GPRC5D • TP53
|
|
Juan-Jose Garces1; Holly Lee2; Ross Firestone1; Ozgur Eren1; Bachisio Ziccheddu1; Christine Riedhammer3; Jan Frenking4; Kylee Maclachlan1; Jesus Gutierrez Abril1; Sarun Sereewattanawoot1; Eric Smith5; Ernesta P. Neri2; Benjamin G. Barwick6; Vikas A. Gupta6; Lawrence Boise6; Michael Kluck1; Ahmet Dogan1; Issam Hamadeh1; Marc S. Raab4; Leo Rasche3; Nizar J. Bahlis2; Karlo Perica1; Sham Mailankody1; Saad Z. Usmani1; Francesco Maura1
|